

**UNITED STATES SECURITIES AND EXCHANGE
COMMISSION**

Washington, D.C. 20549

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES**

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden

hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Widman Fredrik</u> (Last) (First) (Middle) <u>1020 KIFER ROAD</u> (Street) <u>SUNNYVALE CA 94086</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>01/01/2022</u>	3. Issuer Name and Ticker or Trading Symbol <u>INTUITIVE SURGICAL INC [ISRG]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>See Remarks</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Common Stock</u>	<u>1,104</u>	<u>D</u>	

**Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<u>Non-Qualified Stock Option (right to buy)</u>	<u>(1)</u>	<u>08/17/2025</u>	<u>Common Stock</u>	<u>1,224</u>	<u>59.2278</u>	<u>D</u>	
<u>Non-Qualified Stock Option (right to buy)</u>	<u>(2)</u>	<u>02/16/2026</u>	<u>Common Stock</u>	<u>159</u>	<u>59.4622</u>	<u>D</u>	
<u>Non-Qualified Stock Option (right to buy)</u>	<u>(1)</u>	<u>08/15/2026</u>	<u>Common Stock</u>	<u>1,908</u>	<u>76.9989</u>	<u>D</u>	
<u>Non-Qualified Stock Option (right to buy)</u>	<u>(2)</u>	<u>02/15/2027</u>	<u>Common Stock</u>	<u>1,638</u>	<u>79.6378</u>	<u>D</u>	
<u>Non-Qualified Stock Option (right to buy)</u>	<u>(1)</u>	<u>08/15/2027</u>	<u>Common Stock</u>	<u>1,629</u>	<u>109.4856</u>	<u>D</u>	
<u>Non-Qualified Stock Option (right to buy)</u>	<u>(2)</u>	<u>02/15/2028</u>	<u>Common Stock</u>	<u>975</u>	<u>139.52</u>	<u>D</u>	
<u>Non-Qualified Stock Option (right to buy)</u>	<u>(1)</u>	<u>08/15/2029</u>	<u>Common Stock</u>	<u>786</u>	<u>166.6233</u>	<u>D</u>	
<u>Non-Qualified Stock Option (right to buy)</u>	<u>(1)</u>	<u>08/15/2028</u>	<u>Common Stock</u>	<u>975</u>	<u>174.2567</u>	<u>D</u>	
<u>Non-Qualified Stock Option (right to buy)</u>	<u>(2)</u>	<u>02/28/2030</u>	<u>Common Stock</u>	<u>1,701</u>	<u>177.9867</u>	<u>D</u>	
<u>Non-Qualified Stock Option (right to buy)</u>	<u>(2)</u>	<u>02/15/2029</u>	<u>Common Stock</u>	<u>789</u>	<u>182.8333</u>	<u>D</u>	
<u>Non-Qualified Stock Option (right to buy)</u>	<u>(1)</u>	<u>08/28/2030</u>	<u>Common Stock</u>	<u>1,701</u>	<u>242.3367</u>	<u>D</u>	

**Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Non-Qualified Stock Option (right to buy)	(2)	02/26/2031	Common Stock	1,218	245.6	D	
Non-Qualified Stock Option (right to buy)	(1)	08/26/2031	Common Stock	1,218	347.4167	D	
Restricted Stock Units	(3)	02/15/2028	Common Stock	486	0.00	D	
Restricted Stock Units	(3)	02/15/2029	Common Stock	786	0.00	D	
Restricted Stock Units	(3)	02/28/2030	Common Stock	2,550	0.00	D	
Restricted Stock Units	(3)	02/26/2031	Common Stock	2,433	0.00	D	

Explanation of Responses:

1. Non-statutory stock option granted pursuant to the 2010 Incentive Award Plan. The option vests 7/48th one month after the date of grant and 1/48th monthly thereafter.
2. Non-statutory stock option granted pursuant to the 2010 Incentive Award Plan. The option vests 1/8th six months after the date of grant and 1/48th monthly thereafter.
3. Each RSU granted represents a contingent right to receive one share of Intuitive Surgical common stock. The grant vests 25% on the first anniversary of the date of grant and annually thereafter, over a four year period.

Remarks:

Title: Vice President, Corporate Controller (Principal Accounting Officer) Exhibit 24.1 - Power of Attorney

By: Donna Spinola For: 01/10/2022
Fredrik Widman

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

Know all by these present that the undersigned hereby authorizes (i) Lydia Terrill, (ii) Donna Spinola, (iii) Brian King and (iv) Siang Chin of Intuitive Surgical, Inc.(the “**Company**”) and (v) Mark V. Roeder of Latham & Watkins LLP and each of them individually to execute for and on behalf of the undersigned, in the undersigned’s capacity as an officer and/or director of the Company, Forms 3, 4 and 5, and other forms as may be required, any amendments thereto, and cause such form(s) to be filed with the U.S. Securities and Exchange Commission (the “**SEC**”) pursuant to Section 16(a) of the Securities Act of 1934, relating to the undersigned’s beneficial ownership of securities in the Company. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned’s holdings of, and transactions in, securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 12th day of November 2021.

/s/ Fredrik Widman

Signature

Fredrik Widman

Print Name